Onesource Specialty Pharma Limited has informed the Exchange about Copy of Newspaper Publication
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Onesource Specialty Pharma (formerly Stelis Biopharma) submitted to BSE and NSE copies of newspaper advertisements published on May 7, 2025 in Business Standard and Lokmat, disclosing its audited Q4 and full-year FY25 results as required under SEBI Listing Regulations 47 and 52(8). On a consolidated basis, total income from operations rose to Rs. 175,402.27 lakhs in FY25 from Rs. 126,507.84 lakhs in FY24, a growth of about 39%. Net profit after tax for FY25 stood at Rs. 75,124.61 lakhs versus Rs. 61,189.66 lakhs in FY24. For Q4 FY25 alone, consolidated net profit after tax was Rs. 19,070.53 lakhs on total income of Rs. 42,400.60 lakhs. Consolidated net worth strengthened to Rs. 4,31,685.18 lakhs and basic EPS for FY25 came in at Rs. 15.04. The results were reviewed by the Audit Committee and approved by the Board on May 6, 2025.
Strong year-on-year growth in both revenue and profit signals improving business momentum, which is supportive for shareholder value; however, the filing itself is only a regulatory newspaper publication of already-approved results, so no new price-moving action is expected from this disclosure.